Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Molecular Determinants of the Differential Modulation of Cav1.2 and Cav1.3 by Nifedipine and FPL 64176.

Wang Y, Tang S, Harvey KE, Salyer AE, Li TA, Rantz EK, Lill MA, Hockerman GH.

Mol Pharmacol. 2018 Sep;94(3):973-983. doi: 10.1124/mol.118.112441. Epub 2018 Jul 6.

PMID:
29980657
2.

Agonists of the γ-aminobutyric acid type B (GABAB) receptor derived from β-hydroxy and β-amino difluoromethyl ketones.

Sowaileh MF, Salyer AE, Roy KK, John JP, Woods JR, Doerksen RJ, Hockerman GH, Colby DA.

Bioorg Med Chem Lett. 2018 Sep 1;28(16):2697-2700. doi: 10.1016/j.bmcl.2018.04.003. Epub 2018 Apr 7.

PMID:
29657102
3.

Corrigendum to "The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux" [Biochem. Pharmacol. 120 (2016) 46-55].

Sealover NR, Felts B, Kuntz CP, Jarrard RE, Hockerman GH, Lamb PW, Barker EL, Henry LK.

Biochem Pharmacol. 2018 Jan;147:9. doi: 10.1016/j.bcp.2017.11.001. Epub 2017 Nov 28. No abstract available.

PMID:
29195124
4.

The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux.

Sealover NR, Felts B, Kuntz CP, Jarrard RE, Hockerman GH, Lamb PW, Barker EL, Henry LK.

Biochem Pharmacol. 2016 Nov 15;120:46-55. doi: 10.1016/j.bcp.2016.09.006. Epub 2016 Sep 13. Erratum in: Biochem Pharmacol. 2017 Nov 28;147:9.

PMID:
27638414
5.

Bimolecular Fluorescence Complementation (BiFC) Analysis of Protein-Protein Interactions and Assessment of Subcellular Localization in Live Cells.

Pratt EP, Owens JL, Hockerman GH, Hu CD.

Methods Mol Biol. 2016;1474:153-70. doi: 10.1007/978-1-4939-6352-2_9.

PMID:
27515079
6.

Ca2+ influx through L-type Ca2+ channels and Ca2+-induced Ca2+ release regulate cAMP accumulation and Epac1-dependent ERK 1/2 activation in INS-1 cells.

Pratt EP, Salyer AE, Guerra ML, Hockerman GH.

Mol Cell Endocrinol. 2016 Jan 5;419:60-71. doi: 10.1016/j.mce.2015.09.034. Epub 2015 Oct 3.

7.

Activation of the γ-Aminobutyric Acid Type B (GABA(B)) Receptor by Agonists and Positive Allosteric Modulators.

Brown KM, Roy KK, Hockerman GH, Doerksen RJ, Colby DA.

J Med Chem. 2015 Aug 27;58(16):6336-47. doi: 10.1021/jm5018913. Epub 2015 Apr 24. Review.

PMID:
25856547
8.

The Ubr2 Gene is Expressed in Skeletal Muscle Atrophying as a Result of Hind Limb Suspension, but not Merg1a Expression Alone.

Hockerman GH, Dethrow NM, Hameed S, Doran M, Jaeger C, Wang WH, Pond AL.

Eur J Transl Myol. 2014 Mar 31;24(3):3319. doi: 10.4081/ejtm.2014.3319. eCollection 2014 Sep 23.

9.

Uncoupling of Cav1.2 from Ca(2+)-induced Ca(2+) release and SK channel regulation in pancreatic β-cells.

Wang Y, Jarrard RE, Pratt EP, Guerra ML, Salyer AE, Lange AM, Soderling IM, Hockerman GH.

Mol Endocrinol. 2014 Apr;28(4):458-76. doi: 10.1210/me.2013-1094. Epub 2014 Feb 7.

10.

Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor.

Conley JM, Brand CS, Bogard AS, Pratt EP, Xu R, Hockerman GH, Ostrom RS, Dessauer CW, Watts VJ.

J Pharmacol Exp Ther. 2013 Nov;347(2):276-87. doi: 10.1124/jpet.113.207449. Epub 2013 Sep 5.

11.

The mERG1a channel modulates skeletal muscle MuRF1, but not MAFbx, expression.

Pond AL, Nedele C, Wang WH, Wang X, Walther C, Jaeger C, Bradley KS, Du H, Fujita N, Hockerman GH, Hannon KM.

Muscle Nerve. 2014 Mar;49(3):378-88. doi: 10.1002/mus.23924. Epub 2013 Aug 30.

12.

Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor.

Han C, Salyer AE, Kim EH, Jiang X, Jarrard RE, Powers MS, Kirchhoff AM, Salvador TK, Chester JA, Hockerman GH, Colby DA.

J Med Chem. 2013 Mar 28;56(6):2456-65. doi: 10.1021/jm301805e. Epub 2013 Mar 6.

PMID:
23428109
13.

Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx.

Jarrard RE, Wang Y, Salyer AE, Pratt EP, Soderling IM, Guerra ML, Lange AM, Broderick HJ, Hockerman GH.

Mol Pharmacol. 2013 Jan;83(1):191-205. doi: 10.1124/mol.112.081943. Epub 2012 Oct 15.

14.
15.

Interaction of diltiazem with an intracellularly accessible binding site on Ca(V)1.2.

Shabbir W, Beyl S, Timin EN, Schellmann D, Erker T, Hohaus A, Hockerman GH, Hering S.

Br J Pharmacol. 2011 Mar;162(5):1074-82. doi: 10.1111/j.1476-5381.2010.01091.x.

16.

Cav1.2 and Cav1.3 are differentially coupled to glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion in the pancreatic beta-cell line INS-1.

Jacobo SM, Guerra ML, Hockerman GH.

J Pharmacol Exp Ther. 2009 Nov;331(2):724-32. doi: 10.1124/jpet.109.158519. Epub 2009 Aug 26.

17.

The intracellular II-III loops of Cav1.2 and Cav1.3 uncouple L-type voltage-gated Ca2+ channels from glucagon-like peptide-1 potentiation of insulin secretion in INS-1 cells via displacement from lipid rafts.

Jacobo SM, Guerra ML, Jarrard RE, Przybyla JA, Liu G, Watts VJ, Hockerman GH.

J Pharmacol Exp Ther. 2009 Jul;330(1):283-93. doi: 10.1124/jpet.109.150672. Epub 2009 Apr 7.

18.

Kv11.1 channel subunit composition includes MinK and varies developmentally in mouse cardiac muscle.

Wang X, Xu R, Abernathey G, Taylor J, Alzghoul MB, Hannon K, Hockerman GH, Pond AL.

Dev Dyn. 2008 Sep;237(9):2430-7. doi: 10.1002/dvdy.21671.

19.

Adenoviral-mediated expression of dihydropyridine-insensitive L-type calcium channels in cardiac ventricular myocytes and fibroblasts.

Walsh KB, Zhang J, Fuseler JW, Hilliard N, Hockerman GH.

Eur J Pharmacol. 2007 Jun 22;565(1-3):7-16. Epub 2007 Mar 3.

PMID:
17397827
20.

Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway.

Wang X, Hockerman GH, Green HW 3rd, Babbs CF, Mohammad SI, Gerrard D, Latour MA, London B, Hannon KM, Pond AL.

FASEB J. 2006 Jul;20(9):1531-3. Epub 2006 May 24.

PMID:
16723379
21.

Antibody inhibition of synaptosomal protein of 25 kDa (SNAP-25) and syntaxin 1 reduces rapid exocytosis in insulin-secreting cells.

Vikman J, Ma X, Hockerman GH, Rorsman P, Eliasson L.

J Mol Endocrinol. 2006 Jun;36(3):503-15.

PMID:
16720719
23.

Differential antifungal and calcium channel-blocking activity among structurally related plant defensins.

Spelbrink RG, Dilmac N, Allen A, Smith TJ, Shah DM, Hockerman GH.

Plant Physiol. 2004 Aug;135(4):2055-67. Epub 2004 Aug 6.

24.

Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2.

Dilmac N, Hilliard N, Hockerman GH.

Mol Pharmacol. 2004 Nov;66(5):1236-47. Epub 2004 Jul 30.

25.
26.

Nanoprobe implantation into mammalian cells by cationic transfection.

Zhao Y, Sadtler B, Lin M, Hockerman GH, Wei A.

Chem Commun (Camb). 2004 Apr 7;(7):784-5. Epub 2004 Mar 4.

PMID:
15045062
27.
28.

Ca v 1.3 is preferentially coupled to glucose-stimulated insulin secretion in the pancreatic beta-cell line INS-1.

Liu G, Dilmac N, Hilliard N, Hockerman GH.

J Pharmacol Exp Ther. 2003 Apr;305(1):271-8.

29.

The virally encoded fungal toxin KP4 specifically blocks L-type voltage-gated calcium channels.

Gage MJ, Rane SG, Hockerman GH, Smith TJ.

Mol Pharmacol. 2002 Apr;61(4):936-44.

30.

Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca(2+) channels.

Hockerman GH, Dilmac N, Scheuer T, Catterall WA.

Mol Pharmacol. 2000 Dec;58(6):1264-70.

31.

Construction of a high-affinity receptor site for dihydropyridine agonists and antagonists by single amino acid substitutions in a non-L-type Ca2+ channel.

Hockerman GH, Peterson BZ, Sharp E, Tanada TN, Scheuer T, Catterall WA.

Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14906-11.

32.
33.

Analysis of the dihydropyridine receptor site of L-type calcium channels by alanine-scanning mutagenesis.

Peterson BZ, Johnson BD, Hockerman GH, Acheson M, Scheuer T, Catterall WA.

J Biol Chem. 1997 Jul 25;272(30):18752-8.

34.
35.

Modulation of the cloned skeletal muscle L-type Ca2+ channel by anchored cAMP-dependent protein kinase.

Johnson BD, Brousal JP, Peterson BZ, Gallombardo PA, Hockerman GH, Lai Y, Scheuer T, Catterall WA.

J Neurosci. 1997 Feb 15;17(4):1243-55.

36.

Molecular determinants of drug binding and action on L-type calcium channels.

Hockerman GH, Peterson BZ, Johnson BD, Catterall WA.

Annu Rev Pharmacol Toxicol. 1997;37:361-96. Review.

PMID:
9131258
37.

Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines.

Johnson BD, Hockerman GH, Scheuer T, Catterall WA.

Mol Pharmacol. 1996 Nov;50(5):1388-400.

PMID:
8913371
38.

Antagonist conformations with the beta(2)-adrenergic receptor ligand binding pocket.

Hockerman GH, Girvin ME, Malbon CC, Ruoho AE.

Mol Pharmacol. 1996 Jun;49(6):1021-32.

PMID:
8649340
39.

Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels.

Hockerman GH, Johnson BD, Scheuer T, Catterall WA.

J Biol Chem. 1995 Sep 22;270(38):22119-22.

Supplemental Content

Loading ...
Support Center